CMV prevention and treatment in transplantation: What’s new in 2019 Review


Authors: Stern, A.; Papanicolaou, G. A.
Review Title: CMV prevention and treatment in transplantation: What’s new in 2019
Abstract: Purpose of Review: Transplant recipients are at risk for cytomegalovirus (CMV) infection and associated morbidity and mortality. We summarize recently introduced or currently investigated modalities for prevention and treatment of CMV infection in hematopoietic cell (HCT) and solid organ transplant (SOT) recipients. Recent Findings: Letermovir was recently approved for CMV prevention in HCT recipients. Data from real world studies support its role to improve outcomes in this population. Letermovir is currently under investigation for broader patient populations and indications. Maribavir is in late stages of development for CMV treatment and may provide a safer alternative to currently available anti-CMV drugs. Promising CMV vaccine candidates and adoptive cell therapy approaches are under evaluation. CMV immune monitoring assays are predicted to play a more central role in our clinical decision making. Summary: In recent years, major advances have been made in CMV prevention and treatment in transplant recipients. Rigorous research is ongoing and is anticipated to further impact our ability to improve outcomes in this population. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Keywords: prophylaxis; cytomegalovirus (cmv); hematopoietic cell transplant (hct); cell-mediated immunity (cmi); preemptive treatment; solid organ transplant (sot)
Journal Title: Current Infectious Disease Reports
Volume: 21
Issue: 11
ISSN: 1523-3847
Publisher: Springer  
Date Published: 2019-11-01
Start Page: 45
Language: English
DOI: 10.1007/s11908-019-0699-0
PROVIDER: scopus
PUBMED: 31732823
DOI/URL:
Notes: Review -- Export Date: 2 December 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Anat Stern
    13 Stern